Alliance Global Partners initiates coverage on Scilex Holding Company (SCLX) with a ‘Buy’ rating and a $14 price target. The bullish outlook is driven by the potential of SEMDEXA, a non-opioid injectable corticosteroid gel for sciatica, to reach blockbuster status. The company’s board is exploring strategic options, including a potential spinoff or dividend distribution.